Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Bidirectional Optical Control of Proton Motive Force in Escherichia coli Using Microbial Rhodopsins by Kotaro Nakanishi (3389300)

Bidirectional Optical Control of Proton Motive Force in Escherichia coli Using Microbial Rhodopsins by Kotaro Nakanishi (3389300)

Bidirectional Optical Control of Proton Motive Force in Escherichia coli Using Microbial Rhodopsins by Kotaro Nakanishi (3389300)

Bidirectional Optical Control of Proton Motive Force in Escherichia coli Using Microbial Rhodopsins by Kotaro Nakanishi (3389300)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Novel chromobox 2 inhibitory peptide decreases tumor progression by Lindsay W. Brubaker (15099942)

VEGFa, VEGFR1 and VEGFR2 mRNA levels following A2E incubation and/or light exposure. by Mélanie Marie (7535228)

NRX-1 localization to cholinergic axons is decreased in <i>unc-104</i> mutants and colocalizes with UNC-104 in cholinergic axon terminals. by Devyn Oliver (12015660)

A noxious temperature decrease without a prior increase produces a subtly larger decrease in pain intensity. by Benedict J. Alter (9745466)

eIF5a is up-regulated in unruptured AAAs and decreased in ruptured AAAs. by Dong Ma (584680)

Summary of electrical energy and dose to achieve 4-log inactivation (LI) of E. coli. PBS = phosphate buffered saline; NOM = natural organic matter (3 mg/L SRNOM); values are mean ±... by Daniel Ma (12698752)

Estimated mean lichen species richness vs. distance to the DMTS haul road in Cape Krusenstern National Monument, Alaska, on a log-log scale from a Bayesian posterior predictions mo... by Peter N. Neitlich (4034300)

Subjects:

The human neutrophil IL-1β secretory response, in contrast to the CXCL8/IL-8 secretory response decreases as MOI increases. by Florencia Sabbione (4862455)

HoxA9-ER directly represses <i>Cebpa</i> gene expression in myeloid cells. by Lei Peng (260321)

AUM302 and TP-3654 decrease the cell viability of MIA PaCa-2 gemcitabine-resistant (GemR) cell line. by Komala Ingle (17364491)

PKCλ KD leads to decreases in CD133-positive cells. by Yuka Nozaki (9115620)

FTY720 treatment decreased phosphorylation of AKT, ERK, and c-myc. by Laura L. Stafman (6577184)